Peapod Lane Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Peapod Lane Capital’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-272,820	Closed	-$1.44M	–	63
2026 Q1	$1.44M	Sell	272,820 -162,200	-37%	-$745K	1.18%	39
2025 Q4	$1.55M	Sell	435,020 -22,196	-5%	-$70.5K	1.32%	34
2025 Q3	$1.33M	Buy	457,216 +4,748	+1%	+$16.2K	1.19%	40
2025 Q2	$1.63M	Buy	452,468 +408	+0.1%	+$1.22K	1.63%	28
2025 Q1	$1.35M	Buy	452,060 +123,479	+38%	+$385K	1.52%	26
2024 Q4	$1.1M	Buy	+328,581	New	+$1.09M	1.09%	37

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Peapod Lane Capital's AVIR Position: Q2 2026 in Review

Peapod Lane Capital sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 272,820 shares — an estimated $1.44M sold.

Peapod Lane Capital first reported a position in AVIR in Q4 2024 and held it in 6 quarters. The position peaked at $1.63M in Q2 2025. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Peapod Lane Capital reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Peapod Lane Capital sold 272,820 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Peapod Lane Capital first reported a position in Atea Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Peapod Lane Capital's Atea Pharmaceuticals position peaked at $1.63M in Q2 2025.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.